COVID-19 and the effects on pulmonary function following infection: A retrospective analysis.

EClinicalMedicine

Department of Pulmonary and Critical Care Medicine, Mayo Clinic, 4500 San Pablo Rd S., Jacksonville, FL, 32224, USA.

Published: September 2021

AI Article Synopsis

  • The study aimed to compare pre-infection and post-infection pulmonary function tests (PFT) in COVID-19 patients to distinguish effects of the virus from existing conditions.
  • A cohort of 80 patients was analyzed, showing no significant changes in key PFT metrics before and after infection, regardless of disease severity or hospitalization needs.
  • Age and specific pre-existing conditions like interstitial lung disease were linked to reduced lung function, suggesting these factors may play a role in post-infection outcomes, rather than the virus itself causing significant impairment.

Article Abstract

Background: The coronavirus disease 2019 (COVID-19) has been identified in over 110 million people with no studies comparing pre-infection pulmonary function to post-infection. This study's aim was to compare pre-infection and post-infection pulmonary function tests (PFT) in COVID-19 infected patients to better delineate between preexisting abnormalities and effects of the virus.

Methods: This was a retrospective multi-center cohort study. Patients were identified based on having COVID-19 and a pre- and post-infection PFT within one year of infection during the time period of March 1, 2020 to November 10, 2020.

Findings: There was a total of 80 patients, with an even split in gender; the majority were white ( = 70, 87·5%) and never smokers ( = 42, 52·5%). The majority had mild to moderate COVID-19 disease ( = 60, 75·1%) with 25 (31·2%) requiring hospitalization. There was no difference between the pre- and post-PFT data, specifically with the forced vital capacity (FVC) ( = 0·52), forced expiratory volume in 1 s (FEV1)( = 0·96), FEV1/FVC( = 0·66), total lung capacity (TLC) ( = 0·21), and diffusion capacity (DLCO)( = 0·88). There was no difference in the PFT when analyzed by hospitalization and disease severity. After adjusting for potential confounders, interstitial lung disease (ILD) was independently associated with a decreased FEV1 (-2·6 [95% CI, -6·7 to - 1·6] vs. -10·3 [95% CI, -17·7 to -2·9];  = 0·03) and an increasing age ( = 0·01) and cystic fibrosis (-1·1 [95% CI, -4·5 to- 2·4] vs. -36·5 [95% CI, -52·1 to -21·0];  < 0·01) were associated with decreasing FVC when comparing pre and post infection PFT. Only increasing age was independently associated with a reduction in TLC ( = 0·01) and DLCO ( = 0·02) before and after infection.

Interpretation: This study showed that there is no difference in pulmonary function as measured by PFT before and after COVID-19 infection in non-critically ill classified patients. There could be a relationship with certain underlying lung diseases (interstitial lung disease and cystic fibrosis) and decreased lung function following infection. This information should aid clinicians in their interpretation of pulmonary function tests obtained following COVID-19 infection.

Funding: No funding was obtained for this study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360709PMC
http://dx.doi.org/10.1016/j.eclinm.2021.101079DOI Listing

Publication Analysis

Top Keywords

pulmonary function
12
covid-19
5
covid-19 effects
4
effects pulmonary
4
function infection
4
infection retrospective
4
retrospective analysis
4
analysis background
4
background coronavirus
4
disease
4

Similar Publications

The widespread application of genome editing to treat and cure disease requires the delivery of genome editors into the nucleus of target cells. Enveloped delivery vehicles (EDVs) are engineered virally derived particles capable of packaging and delivering CRISPR-Cas9 ribonucleoproteins (RNPs). However, the presence of lentiviral genome encapsulation and replication proteins in EDVs has obscured the underlying delivery mechanism and precluded particle optimization.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events (irAEs), with thyroid irAEs being the most common endocrine-related irAEs. The incidence of overt thyroid irAEs ranged 8.9-22.

View Article and Find Full Text PDF

Mycobacterium abscessus is a rapidly growing nontuberculous mycobacterium that causes severe pulmonary infections. Recent studies indicate that ferroptosis may play a critical role in the pathogenesis of M. abscessus pulmonary disease.

View Article and Find Full Text PDF

Based on network pharmacology and molecular docking methods, this study explored its active compounds and confirmed its potential mechanism of action against Hand-foot skin reaction induced by tumor-targeted drugs. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and UniProt Database were used to obtain the active ingredients and target proteins of Spatholobi Caulis. All hand-foot skin reaction (HFSR)-related targets were obtained with the help of the Human Gene Database, Online Mendelian Inheritance in Humans (OMIM), DisGeNET and DrugBank databases.

View Article and Find Full Text PDF

TSLP acts on regulatory T cells to maintain their identity and limit allergic inflammation.

Sci Immunol

January 2025

Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.

Thymic stromal lymphopoietin (TSLP) is a type I cytokine that promotes allergic responses and mediates type 2 immunity. A balance between effector T cells (T), which drive the immune response, and regulatory T cells (T), which suppress the response, is required for proper immune homeostasis. Here, we report that TSLP differentially acts on T versus T to balance type 2 immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!